Neutral endopeptidase and angiotensin-converting enzyme - key enzymes terminating the action of neuroendocrine mediators

被引:43
|
作者
Scholzen, TE [1 ]
Luger, TA [1 ]
机构
[1] Univ Munster, Dept Dermatol, Ludwig Boltzmann Inst Cell Biol & Immunobiol Skin, D-48149 Munster, Germany
关键词
allergic contact dermatitis; angiotensin-converting enzyme; neuroimmunology; neutral endopeptidase; skin;
D O I
10.1111/j.1600-0625.2004.00260.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Zinc-metalloproteases, such as neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), effectively control the bioavailability of peptide mediators released from sensory nerves, immune and skin cells during the cutaneous response to endogenous or exogenous noxious stimuli. Functional inactivation of NEP or ACE by transient inhibition or permanent genomic deletion results in a relative abundance of substance P (SP) and bradykinin (BK); this augments murine allergic contact dermatitis (ACD) by affecting ACD sensitization and elicitation, which involves neurokinin 1 receptors (NK1), BK receptors (B-2) and an intact cutaneous sensory nervous system. Present evidence suggests that increased SP via NK1 is capable of boosting important functions of SP- and NK1-expressing dendritic cells (DCs) and T cells (TCs) in an auto- or paracrine manner, which promotes ACD antigen sensitization. Moreover, skin inflammation or wounding in vivo, as well as treatment of epidermal and dermal cells by UV light and inflammatory mediators in vitro, regulates NEP and ACE expression and activity. Likewise, NEP and ACE are capable of processing neuroendocrine hormones, such as adrenocorticotropin and alpha-melanocyte-stimulating hormone. Thus, present data indicate that ACE and NEP, via proteolytic cleavage of peptide mediators and growth factors, represent important control factors for the inflammatory response in skin disorders such as psoriasis or allergic inflammation, but may also be capable of affecting pigmentation, cell survival, wound healing and tissue regeneration.
引用
收藏
页码:22 / 26
页数:5
相关论文
共 50 条
  • [1] INHIBITION OF EITHER ANGIOTENSIN-CONVERTING ENZYME OR NEUTRAL ENDOPEPTIDASE INDUCES BOTH ENZYMES
    HELIN, K
    TIKKANEN, I
    HOHENTHAL, U
    FYHRQUIST, F
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 264 (02) : 135 - 141
  • [2] A COMPARISON OF THE PROPERTIES AND ENZYMATIC-ACTIVITIES OF 3 ANGIOTENSIN PROCESSING ENZYMES - ANGIOTENSIN-CONVERTING ENZYME, PROLYL ENDOPEPTIDASE AND NEUTRAL ENDOPEPTIDASE 24.11
    WELCHES, WR
    BROSNIHAN, KB
    FERRARIO, CM
    LIFE SCIENCES, 1993, 52 (18) : 1461 - 1480
  • [3] In vivo pharmacology of dual neutral endopeptidase/angiotensin-converting enzyme inhibitors
    Seymour, AA
    Asaad, MM
    AbboaOffei, BE
    Smith, PL
    Rogers, WL
    Dorso, CR
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 28 (05) : 672 - 678
  • [4] DUAL INHIBITION OF ANGIOTENSIN-CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE IN RATS WITH HYPERTENSION
    FRENCH, JF
    ANDERSON, BA
    DOWNS, TR
    DAGE, RC
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 26 (01) : 107 - 113
  • [5] Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: Influence of bradykinin
    Pham, I
    Gonzalez, W
    Doucet, J
    FournieZaluski, MC
    Roques, BP
    Michel, JB
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 296 (03) : 267 - 276
  • [6] Design and pharmacology of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors
    DeLombaert, S
    Chatelain, RE
    Fink, CA
    Trapani, AJ
    CURRENT PHARMACEUTICAL DESIGN, 1996, 2 (05) : 443 - 462
  • [7] Design of orally active dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme with long duration of action
    FournieZaluski, MC
    Coric, P
    Thery, V
    Gonzalez, W
    Meudal, H
    Turcaud, S
    Michel, JB
    Roques, BP
    JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (13) : 2594 - 2608
  • [8] CGS 30440: A dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11
    Cohen, DS
    Fink, CA
    Trapani, AJ
    Webb, RL
    Zane, PA
    Chatelain, RE
    CARDIOVASCULAR DRUG REVIEWS, 1999, 17 (01): : 16 - 38
  • [9] Recent advances in the development of dual angiotensin-converting enzyme and neutral endopeptidase inhibitors
    Fink, CA
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1996, 6 (11) : 1147 - 1164
  • [10] Role of angiotensin-converting enzyme and neutral endopeptidase in flow-dependent remodeling
    Korshunov, VA
    Massett, MP
    Carey, RM
    Berk, BC
    JOURNAL OF VASCULAR RESEARCH, 2004, 41 (02) : 148 - 156